WuXi NextCODE

OverviewSuggest Edit

WuXi NextCODE enables organizations worldwide to use the full power of the genome to improve health and support wellness. We do that by providing the most powerful technology platform for using sequence data – at scale, real-time, online - as well as all the capabilities and know-how required to generate and deploy the data you need to identify the key variants in the genome that underlie your patients’ phenotype. Along with uniquely powerful means of using your genomic data, WuXi NextCODE offers deep expertise and end-to-end solutions for generating and deploying it. These include clinical diagnostics and applications; a full range of CAP- and CLIA-certified sequencing; secondary analysis; cloud solutions from leading global providers and the option for HIPAA-compliant storage. We are here to help with whatever piece of the puzzle you are missing or with bundled or completely integrated solutions, customized to meet your needs.
TypePrivate
Founded2013
HQCambridge, MA, US
Websitewuxinextcode.com

Latest Updates

Employees (est.) (Jun 2020)163(-1%)
Job Openings4
Cybersecurity ratingBMore

Key People/Management at WuXi NextCODE

Rob Brainin

Rob Brainin

CEO
Jeffrey Gulcher

Jeffrey Gulcher

CSO & Co-Founder
John Long

John Long

CFO
Hakon Gudbjartsson

Hakon Gudbjartsson

Chief Informatics Officer
Jamie Morris

Jamie Morris

GM, ROW B2B Business
Louis Yuan

Louis Yuan

SVP and China General Manager
Show more

WuXi NextCODE Office Locations

WuXi NextCODE has offices in Cambridge, Zhabei Qu and Reykjavík
Cambridge, MA, US (HQ)
101 Main St
Cambridge, MA, US
55 Cambridge Pkwy
Zhabei Qu, CN
583 Luochuan Middle Rd
Reykjavík, IS
2 Katrínartún
Show all (4)

WuXi NextCODE Financials and Metrics

Summary Metrics

Founding Date

2013

WuXi NextCODE total Funding

$255 m

WuXi NextCODE latest funding size

$165 m

Time since last funding

4 years ago

WuXi NextCODE investors

WuXi NextCODE's latest funding round in September 2017 was reported to be $165 m. In total, WuXi NextCODE has raised $255 m
Show all financial metrics

WuXi NextCODE Cybersecurity Score

Cybersecurity ratingPremium dataset

B

84/100

SecurityScorecard logo

WuXi NextCODE Online and Social Media Presence

Embed Graph

WuXi NextCODE News and Updates

WuXi NextCODE Restructures and Becomes Genuity Science

BOSTON, June 23, 2020 /PRNewswire/ -- WuXi NextCODE today announced plans to restructure its operations and governance in order to best position the company for future growth, ground-breaking offerings for customers, and new collaborations with industry partners. As part of these efforts,...

WuXi NextCODE Launches New State-of-the-art Genetic Analysis Laboratory in U.S. with Illumina's New TruSight 500™ Assay

CAMBRIDGE, Mass. and SHANGHAI, March 30, 2019 /PRNewswire/ -- WuXi NextCODE, a global genomic data and insights company, is expanding its laboratory footprint into the U.S. with the opening of a state-of-the-art, CLIA-certified and CAP-accredited genetic analysis laboratory in Woburn,...

WuXi NextCODE names top exec, scores $240 million in funding

Company will continue to push toward digitizing, managing and analyzing genomic big data.

WuXi NextCODE Blogs

For Clinicians

The post For Clinicians appeared first on Genuity Science.

AI Pinpoints Novel Biological Mechanism Causing Aortic Aneurysm

Latest cardiovascular disease breakthrough in partnership with Yale single-cell biology team provides validated starting point for the development of new therapeutics and disease prevention strategies The post AI Pinpoints Novel Biological Mechanism Causing Aortic Aneurysm appeared first on WuXi Nex…

ASHG 2019

The post ASHG 2019 appeared first on WuXi NextCODE.

Privacy & Security

The post Privacy & Security appeared first on WuXi NextCODE.

Bio-IT 2019

Want to harness genomic big data to propel drug discovery, clinical diagnoses, and precision medicine? Hear from our world-leading genomics experts at the annual AACR 2019 meeting in Atlanta, Georgia. The post Bio-IT 2019 appeared first on WuXi NextCODE.

WuXi NextCODE to Offer The New Pan-Cancer TSO 500 Biomarker Assay from Illumina

WuXi NextCODE offers access to Illumina's TruSightTM Oncology 500 (TSO 500), and is an early entrant in Illumina’s Analytical Evaluation Program, which allows access to TSO 500 analytical evaluation service tools. The post WuXi NextCODE to Offer The New Pan-Cancer TSO 500 Biomarker Assay from Illumi…
Show more

WuXi NextCODE Frequently Asked Questions

  • When was WuXi NextCODE founded?

    WuXi NextCODE was founded in 2013.

  • Who are WuXi NextCODE key executives?

    WuXi NextCODE's key executives are Rob Brainin, Jeffrey Gulcher and John Long.

  • How many employees does WuXi NextCODE have?

    WuXi NextCODE has 163 employees.

  • Who are WuXi NextCODE competitors?

    Competitors of WuXi NextCODE include Ontera, Miroculus and Quotient.

  • Where is WuXi NextCODE headquarters?

    WuXi NextCODE headquarters is located at 101 Main St, Cambridge.

  • Where are WuXi NextCODE offices?

    WuXi NextCODE has offices in Cambridge, Zhabei Qu and Reykjavík.

  • How many offices does WuXi NextCODE have?

    WuXi NextCODE has 4 offices.